-
1
-
-
79959956767
-
Robbins Basic Pathology
-
Saunder Elsevier
-
Kumar Vinay, Abbas AK, Fausto N, Mitchell RN. Robbins Basic Pathology, Saunder Elsevier. 2007;8:516-522.
-
(2007)
, vol.8
, pp. 516-522
-
-
Kumar, V.1
Abbas, A.K.2
Fausto, N.3
Mitchell, R.N.4
-
3
-
-
0141853344
-
Tuberculosis (Seminar)
-
Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuberculosis (Seminar), Lancet 2003;362:887-899.
-
(2003)
Lancet
, vol.362
, pp. 887-899
-
-
Frieden, T.R.1
Sterling, T.R.2
Munsiff, S.S.3
Watt, C.J.4
Dye, C.5
-
5
-
-
0037028001
-
Clinical practice. Latent tuberculosis infection
-
Jasmer RM, Nahid P, Hopewell PC "Clinical practice. Latent tuberculosis infection".N. Engl. J. Med.2002;347(23):1860-1866.
-
(2002)
N. Engl. J. Med.
, vol.347
, Issue.23
, pp. 1860-1866
-
-
Jasmer, R.M.1
Nahid, P.2
Hopewell, P.C.3
-
6
-
-
0004260589
-
-
World Health Organization, Retrieved 12 November 2009. Fact sheet No 104
-
"Tuberculosis". World Health Organization. 2007. Retrieved 12 November 2009. Fact sheet No 104.
-
(2007)
Tuberculosis
-
-
-
8
-
-
0027471981
-
Immunopathogenesis of pulmonary tuberculosis
-
Dannenberg AM, Jr. Immunopathogenesis of pulmonary tuberculosis. Hosp Pract 1993;28:51-58.
-
(1993)
Hosp Pract
, vol.28
, pp. 51-58
-
-
Dannenberg Jr., A.M.1
-
9
-
-
0002324068
-
History of tuberculosis
-
In: Bloom BR, editor, Washington, DC: ASM Press
-
Daniel TM, Bates JH, Downes KA. History of tuberculosis. In: Bloom BR, editor. Tuberculosis:Pathogenesis, protection and control. Washington, DC: ASM Press; 1994,13-24.
-
(1994)
Tuberculosis:Pathogenesis, protection and control
, pp. 13-24
-
-
Daniel, T.M.1
Bates, J.H.2
Downes, K.A.3
-
10
-
-
0003081795
-
Pathogenesis of tuberculosis
-
In: Reichman LB, Herschfield E, editor, New York: Marcel Dekker, Inc
-
Nardell E. Pathogenesis of tuberculosis. In: Reichman LB, Herschfield E, editor. Lung biology in health and disease. New York: Marcel Dekker, Inc.1993,103-123.
-
(1993)
Lung biology in health and disease
, pp. 103-123
-
-
Nardell, E.1
-
11
-
-
0017360746
-
Monocyte recruitment in tuberculosis and sarcoidosis
-
Schmitt E, Meuret G, Stix L. Monocyte recruitment in tuberculosis and sarcoidosis. Br J Haematol 1977;35:11-17.
-
(1977)
Br J Haematol
, vol.35
, pp. 11-17
-
-
Schmitt, E.1
Meuret, G.2
Stix, L.3
-
12
-
-
0004102526
-
-
4th edition, Oxford: Pergmon Press
-
Spencer H. Pathology of the lung, 4th edition. Vol 1. Oxford: Pergmon Press; 1985.
-
(1985)
Pathology of the lung
, vol.1
-
-
Spencer, H.1
-
13
-
-
0003970212
-
-
Philadelphia: The WB Saunders Co
-
Youmans GP. Tuberculosis. Philadelphia: The WB Saunders Co; 1979.
-
(1979)
Tuberculosis
-
-
Youmans, G.P.1
-
14
-
-
0002675726
-
Overview of clinical tuberculosis
-
In: Bloom BR, editor, Washington, DC: ASM Press
-
Hopewell PC. Overview of clinical tuberculosis. In: Bloom BR, editor. Tuberculosis: Pathogenesis, protection and control. Washington, DC: ASM Press; 1994. pp 25-46.
-
(1994)
Tuberculosis: Pathogenesis, protection and control
, pp. 25-46
-
-
Hopewell, P.C.1
-
15
-
-
1642497538
-
Identification of risk factors for extrapulmonary tuberculosis
-
Yang Z, Kong Y, Wilson F, Foxman B, Fowler AH, Marrs CF, Cave MD, Bates JH. Identification of risk factors for extrapulmonary tuberculosis. Clin Infect Dis 2004;15, 38(2):199-205.
-
(2004)
Clin Infect Dis
, vol.15-38
, Issue.2
, pp. 199-205
-
-
Yang, Z.1
Kong, Y.2
Wilson, F.3
Foxman, B.4
Fowler, A.H.5
Marrs, C.F.6
Cave, M.D.7
Bates, J.H.8
-
16
-
-
0346364896
-
Extra-pulmonary manifestations in a large metropolitan area with a low incidence of tuberculosis
-
Gonzalez OY, Adams G, Teeter LD, Bui TT, Musser JM, Graviss EA. Extra-pulmonary manifestations in a large metropolitan area with a low incidence of tuberculosis. Int J Tuberc Lung Dis 2003;7(12):1178-1185.
-
(2003)
Int J Tuberc Lung Dis
, vol.7
, Issue.12
, pp. 1178-1185
-
-
Gonzalez, O.Y.1
Adams, G.2
Teeter, L.D.3
Bui, T.T.4
Musser, J.M.5
Graviss, E.A.6
-
17
-
-
84855201910
-
-
An interesting timeline available on
-
History of TB. An interesting timeline available on http://www.indiachestsociety.org/tb/timeline.asp/.
-
History of TB
-
-
-
18
-
-
0042818086
-
Tuberculosis in the twenty-first century: The Indian response
-
Deivanayagam CN. Tuberculosis in the twenty-first century: The Indian response. J Indian Med Assoc 2003;101(3):139.
-
(2003)
J Indian Med Assoc
, vol.101
, Issue.3
, pp. 139
-
-
Deivanayagam, C.N.1
-
19
-
-
0036089343
-
The resurgence of disease: Social and historical perspectives on the 'new' tuberculosis
-
Gandy M, Zumla A. The resurgence of disease: social and historical perspectives on the 'new' tuberculosis. Soc Sci Med 2002;55(3):385-401.
-
(2002)
Soc Sci Med
, vol.55
, Issue.3
, pp. 385-401
-
-
Gandy, M.1
Zumla, A.2
-
21
-
-
0042316991
-
History of tuberculosis control in Ind
-
Mahadev B, Kumar P. History of tuberculosis control in Ind. J Indian Med Assoc 2003;101(3):142-143.
-
(2003)
J Indian Med Assoc
, vol.101
, Issue.3
, pp. 142-143
-
-
Mahadev, B.1
Kumar, P.2
-
22
-
-
1642578221
-
Fluoroquinolones in the treatment of tuberculosis
-
Mitchison DA. Fluoroquinolones in the treatment of tuberculosis. Am J Respir Crit Care Med 2004;169:334-335.
-
(2004)
Am J Respir Crit Care Med
, vol.169
, pp. 334-335
-
-
Mitchison, D.A.1
-
23
-
-
0006350559
-
A five-year assessment of patients in a controlled trial of streptomycin, para-aminosalicylic acid and streptomycin and para-aminosalicylic acid
-
Fox W, Sutherland I. A five-year assessment of patients in a controlled trial of streptomycin, para-aminosalicylic acid and streptomycin and para-aminosalicylic acid. Q J Med 1956;98:221-243.
-
(1956)
Q J Med
, vol.98
, pp. 221-243
-
-
Fox, W.1
Sutherland, I.2
-
24
-
-
2042417395
-
Antimicrobial therapy of pulmonary tuberculosis
-
McDermott W. Antimicrobial therapy of pulmonary tuberculosis. Bull World Health Organ 1960;23:427-461.
-
(1960)
Bull World Health Organ
, vol.23
, pp. 427-461
-
-
McDermott, W.1
-
25
-
-
0026028244
-
Controlled trial of 2, 4 and 6 months of pyrazinamide, in three-timesweekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin and pyrazinamide
-
Hong Kong Chest Service/British Medical Research Council
-
Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4 and 6 months of pyrazinamide, in three-timesweekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin and pyrazinamide. Am Rev Respir Dis 1991;143:700-706.
-
(1991)
Am Rev Respir Dis
, vol.143
, pp. 700-706
-
-
-
27
-
-
61849153021
-
Impact of nanotechnology on drug delivery
-
Farokhzad OC, Langer R., Impact of nanotechnology on drug delivery. ACS Nano. 3(1), 2009,16-20.
-
(2009)
ACS Nano
, vol.3
, Issue.1
, pp. 16-20
-
-
Farokhzad, O.C.1
Langer, R.2
-
28
-
-
76849114174
-
Encyclopedia of infectious diseases: Modern methodologies
-
in: M. Tibayrenc (Ed.), John Wiley & Sons, Hoboken
-
Godreuil S, Tazi L, Bañuls AL. Encyclopedia of infectious diseases: modern methodologies, in: M. Tibayrenc (Ed.), Pulmonary Tuberculosis and Mycobacterium Tuberculosis: Modern Molecular Epidemiology and Perspectives, John Wiley & Sons, Hoboken, 2007,1-30.
-
(2007)
Pulmonary Tuberculosis and Mycobacterium Tuberculosis: Modern Molecular Epidemiology and Perspectives
, pp. 1-30
-
-
Godreuil, S.1
Tazi, L.2
Bañuls, A.L.3
-
29
-
-
2642554960
-
Tuberculosis in HIV-infected patients: A comprehensive review
-
Aaron L, Saadoun D, Calatroni I, Launay O, Mémain N, Vincent V et al. Tuberculosis in HIV-infected patients: a comprehensive review, Clin. Microbiol. Infect. 2004;10:388-398.
-
(2004)
Clin. Microbiol. Infect.
, vol.10
, pp. 388-398
-
-
Aaron, L.1
Saadoun, D.2
Calatroni, I.3
Launay, O.4
Mémain, N.5
Vincent, V.6
-
30
-
-
33947221977
-
A systematic review of rapid diagnostic tests for the detection of tuberculosis infection
-
Dinnes J, Deeks J, Kunst H, Gibson A, Cummins E, Waugh N et al. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection, Health. Technol. Assess. 2007;11:1-178.
-
(2007)
Health Technol. Assess.
, vol.11
, pp. 1-178
-
-
Dinnes, J.1
Deeks, J.2
Kunst, H.3
Gibson, A.4
Cummins, E.5
Waugh, N.6
-
31
-
-
58149489663
-
Diagnosis of latent tuberculosis: Can we do better?
-
Al-Orainey I. Diagnosis of latent tuberculosis: can we do better? Ann. Thorac. Med. 2009;4: 5-9.
-
(2009)
Ann. Thorac. Med.
, vol.4
, pp. 5-9
-
-
Al-Orainey, I.1
-
32
-
-
0038674868
-
About dendrimers: Structure, physical properties, and applications
-
Bosman AW, Janssen HM, Meijer EW. About dendrimers: structure, physical properties, and applications. Chem Rev 1999;99:1665-88.
-
(1999)
Chem Rev
, vol.99
, pp. 1665-1688
-
-
Bosman, A.W.1
Janssen, H.M.2
Meijer, E.W.3
-
33
-
-
33750127627
-
Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers
-
Kumar PV, Asthana A, Dutta T, Jain NK. Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers, J. Drug Target. 2006;14:546-556.
-
(2006)
J. Drug Target.
, vol.14
, pp. 546-556
-
-
Kumar, P.V.1
Asthana, A.2
Dutta, T.3
Jain, N.K.4
-
34
-
-
33846115676
-
PEGylated dendritic architecture for development of a prolonged drug delivery system of an antitubercular drug
-
Kumar PV, Agashe H, Dutta T, Jain NK. PEGylated dendritic architecture for development of a prolonged drug delivery system of an antitubercular drug, Curr. Drug Deliv. 2007;4:11-19.
-
(2007)
Curr. Drug Deliv.
, vol.4
, pp. 11-19
-
-
Kumar, P.V.1
Agashe, H.2
Dutta, T.3
Jain, N.K.4
-
35
-
-
0022592084
-
Hydroxypropyl-β-cyclodextrin: Preparation and characterization; effects on solubility of drugs
-
Pitha J, Milecki J, Fales H, Pannell L, Uekama K. Hydroxypropyl-β-cyclodextrin: preparation and characterization; effects on solubility of drugs, International Journal of Pharmaceutics. 1986;29(1):73-82.
-
(1986)
International Journal of Pharmaceutics
, vol.29
, Issue.1
, pp. 73-82
-
-
Pitha, J.1
Milecki, J.2
Fales, H.3
Pannell, L.4
Uekama, K.5
-
36
-
-
4143070324
-
Analysis of the molecular association of rifampicin with hydroxypropyl-β-cyclodextrin
-
Ferreira DA, Ferreira AG, Vizzotto L, Federman AN, Gomes A. Analysis of the molecular association of rifampicin with hydroxypropyl-β-cyclodextrin, Braz. J. Pharm. Sci. 2004;1:43-51.
-
(2004)
Braz, J. Pharm. Sci.
, vol.1
, pp. 43-51
-
-
Ferreira, D.A.1
Ferreira, A.G.2
Vizzotto, L.3
Federman, A.N.4
Gomes, A.5
-
37
-
-
0034878524
-
Ofloxacin/β-Cyclodextrin Complexation
-
Koester LS, Guterres SS, Roch ML, Eifler-Lima ML, Zuanazzi JA, Bassani VL. Ofloxacin/β-Cyclodextrin Complexation, Drug Development and Industrial Pharmacy 2001; 27(6):533-540.
-
(2001)
Drug Development and Industrial Pharmacy
, vol.27
, Issue.6
, pp. 533-540
-
-
Koester, L.S.1
Guterres, S.S.2
Roch, M.L.3
Eifler-Lima, M.L.4
Zuanazzi, J.A.5
Bassani, V.L.6
-
38
-
-
33750486186
-
Balasangameshwer
-
Prakash BR, Suresh S, Narendra C. Balasangameshwer, Physicochemical characterization of β-cyclodextrin and hydroxy ethyl β-cyclodextrin complexes of rifampicina, Ars Pharm. 2006;47:37-59.
-
(2006)
Physicochemical characterization of β-cyclodextrin and hydroxy ethyl β-cyclodextrin complexes of rifampicina, Ars Pharm.
, vol.47
, pp. 37-59
-
-
Prakash, B.R.1
Suresh, S.2
Narendra, C.3
-
39
-
-
3843097202
-
Classification of orally administered drug on the World Health Organization model list of essential medicines according to the Biopharmaceutics Classification System
-
Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drug on the World Health Organization model list of essential medicines according to the Biopharmaceutics Classification System, Eur. J. Pharm. Biopharm. 2004;58:265-278.
-
(2004)
Eur. J. Pharm. Biopharm.
, vol.58
, pp. 265-278
-
-
Lindenberg, M.1
Kopp, S.2
Dressman, J.B.3
-
40
-
-
19544364888
-
Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models
-
Lenaerts AJ, Gruppo V, Marietta KS, Johnson CM, Driscoll DK, Tompkins NM. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models, Antimicrob. Agents Chemother. 2005;49: 2294-2301.
-
(2005)
Antimicrob. Agents Chemother.
, vol.49
, pp. 2294-2301
-
-
Lenaerts, A.J.1
Gruppo, V.2
Marietta, K.S.3
Johnson, C.M.4
Driscoll, D.K.5
Tompkins, N.M.6
-
41
-
-
11144356026
-
Cyclodextrins as a potential carrier in drug nebulization
-
Evrard B, Bertholet P, Gueders M, Flament MP, Piel G, Delattre L. Cyclodextrins as a potential carrier in drug nebulization, J. Control. Release 2004;96:403-410.
-
(2004)
J. Control. Release
, vol.96
, pp. 403-410
-
-
Evrard, B.1
Bertholet, P.2
Gueders, M.3
Flament, M.P.4
Piel, G.5
Delattre, L.6
-
42
-
-
0035937592
-
Block copolymer micelles for drug delivery: Design, characterization and biological significance
-
Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance, Adv. Drug Deliv. Rev. 2001;47:113-131.
-
(2001)
Adv. Drug Deliv. Rev.
, vol.47
, pp. 113-131
-
-
Kataoka, K.1
Harada, A.2
Nagasaki, Y.3
-
43
-
-
33751512735
-
Polymeric micelles for drug delivery
-
Croy SR, Kwon GS. Polymeric micelles for drug delivery, Curr. Pharm. Des. 2006;12:4669-4684.
-
(2006)
Curr. Pharm. Des.
, vol.12
, pp. 4669-4684
-
-
Croy, S.R.1
Kwon, G.S.2
-
44
-
-
34248577169
-
Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles as drug delivery agents: Improved hydrosolubility, stability and bioavailability of drugs
-
Chiappetta DA, Sosnik A. Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles as drug delivery agents: Improved hydrosolubility, stability and bioavailability of drugs, Eur. J. Pharm. Biopharm. 2007;66:303-317.
-
(2007)
Eur. J. Pharm. Biopharm.
, vol.66
, pp. 303-317
-
-
Chiappetta, D.A.1
Sosnik, A.2
-
46
-
-
33745531638
-
Potential tuberculostatic agent: Micelle-forming pyrazinamide prodrug
-
Silva M, Ricelli NL, El OS, Valentim CS, Ferreira AG, Sato DN. Potential tuberculostatic agent: micelle-forming pyrazinamide prodrug, Arch. Pharm. Chem. Life Sci. 2006;339:283-290.
-
(2006)
Arch. Pharm. Chem. Life Sci.
, vol.339
, pp. 283-290
-
-
Silva, M.1
Ricelli, N.L.2
El, O.S.3
Valentim, C.S.4
Ferreira, A.G.5
Sato, D.N.6
-
47
-
-
84898695652
-
Preparation of polymeric micelles for use as carriers of tuberculostatic drugs
-
Silva M, Ferreira EI, Leite CQF, Sato DN. Preparation of polymeric micelles for use as carriers of tuberculostatic drugs, Trop. J. Pharm. Res.2007;6:815-824.
-
Trop. J. Pharm. Res
, vol.2007
, pp. 6
-
-
Silva, M.1
Ferreira, E.I.2
Leite, C.Q.F.3
Sato, D.N.4
-
48
-
-
43849093356
-
Monolayers of the lipid derivatives of isoniazid atbthe air/water interface and the formation of self-assembled nanostructures in water
-
Jin Y, Chen S, Xin R, Zhou Y. Monolayers of the lipid derivatives of isoniazid atbthe air/water interface and the formation of self-assembled nanostructures in water, Colloids Surf., B Biointerfaces 2008;64:229-235.
-
(2008)
Colloids Surf., B Biointerfaces
, vol.64
, pp. 229-235
-
-
Jin, Y.1
Chen, S.2
Xin, R.3
Zhou, Y.4
-
49
-
-
0035966497
-
Biodegradable polymeric nanoparticles as drug delivery devices
-
Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices, J. Control. Release 2001;70:1-20.
-
(2001)
J. Control. Release
, vol.70
, pp. 1-20
-
-
Soppimath, K.S.1
Aminabhavi, T.M.2
Kulkarni, A.R.3
Rudzinski, W.E.4
-
50
-
-
15544362279
-
Polymeric particulates to improve oral bioavailability of peptide drugs
-
Delie F, Blanco-Prieto MJ. Polymeric particulates to improve oral bioavailability of peptide drugs, Molecules 2005;10:65-80.
-
(2005)
Molecules
, vol.10
, pp. 65-80
-
-
Delie, F.1
Blanco-Prieto, M.J.2
-
51
-
-
0028837083
-
Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery
-
Brannon-Peppas L. Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery, Int. J. Pharm.1995;116:1-9.
-
Int. J. Pharm
, vol.1995
, pp. 116
-
-
Brannon-Peppas, L.1
-
52
-
-
28844488494
-
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
-
Owens TE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles, Int. J. Pharm. 2006;307:93-102.
-
(2006)
Int. J. Pharm.
, vol.307
, pp. 93-102
-
-
Owens, T.E.1
Peppas, N.A.2
-
53
-
-
0034559933
-
Nanoparticles as antituberculosis drugs carriers: Effect on activity against My cobacterium tuberculosis in human monocyte-derived macrophages
-
Anisimova YV, Gelperina SI, Peloquin CA, Heifets LB. Nanoparticles as antituberculosis drugs carriers: effect on activity against My cobacterium tuberculosis in human monocyte-derived macrophages, J. Nanopart. Res. 2000; 2:165-171.
-
(2000)
J. Nanopart. Res
, vol.2
, pp. 165-171
-
-
Anisimova, Y.V.1
Gelperina, S.I.2
Peloquin, C.A.3
Heifets, L.B.4
-
54
-
-
36048983390
-
Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis
-
Kisich KO, Gelperina SI, Higgins MP, Wilson S, Shipulo E, Oganesyan E. Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis, Int. J. Pharm. 2007;345:154-162.
-
(2007)
Int. J. Pharm.
, vol.345
, pp. 154-162
-
-
Kisich, K.O.1
Gelperina, S.I.2
Higgins, M.P.3
Wilson, S.4
Shipulo, E.5
Oganesyan, E.6
-
55
-
-
54049146207
-
Development of a nanosomal formulation of moxifloxacin based on poly (butyl-2-cyanoacrylate)
-
Shipulo EV, Lyubimov II, Maksimenko OO, Vanchugova LV, Oganesyan EA, Sveshnikov PG. Development of a nanosomal formulation of moxifloxacin based on poly (butyl-2-cyanoacrylate), Pharm. Chem. J. 2008;42:145-149.
-
(2008)
Pharm. Chem. J.
, vol.42
, pp. 145-149
-
-
Shipulo, E.V.1
Lyubimov, I.I.2
Maksimenko, O.O.3
Vanchugova, L.V.4
Oganesyan, E.A.5
Sveshnikov, P.G.6
-
56
-
-
0344010111
-
Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis
-
Pandey R, Zahoor A, Sharma S, Khuller GK. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis, Tuberculosis 2003;83:373-378.
-
(2003)
Tuberculosis
, vol.83
, pp. 373-378
-
-
Pandey, R.1
Zahoor, A.2
Sharma, S.3
Khuller, G.K.4
-
57
-
-
33746623370
-
Pharmacokinetic and pharmacodynamic behavior of antitubercular drugs encapsulated in alginate nanoparticles at two doses
-
Zahoor A, Pandey R, Sharma S, Khuller GK. Pharmacokinetic and pharmacodynamic behavior of antitubercular drugs encapsulated in alginate nanoparticles at two doses, Int. J. Antimicrob. Agents 2006;27:409-416.
-
(2006)
Int. J. Antimicrob. Agents
, vol.27
, pp. 409-416
-
-
Zahoor, A.1
Pandey, R.2
Sharma, S.3
Khuller, G.K.4
-
58
-
-
0016404438
-
Drug carrier potential of liposomes in cancer chemotherapy
-
Gregoriadis G, Wills EJ, Swain CP, Tavill AS. Drug carrier potential of liposomes in cancer chemotherapy, Lancet 1974;1:1313-1316.
-
(1974)
Lancet
, vol.1
, pp. 1313-1316
-
-
Gregoriadis, G.1
Wills, E.J.2
Swain, C.P.3
Tavill, A.S.4
-
59
-
-
0025282170
-
Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice
-
Klemens SP, Cynamon MH, Swenson CE, Ginsberg RS. Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice, Antimicrob. Agents Chemother. 1990;34:967-970.
-
(1990)
Antimicrob. Agents Chemother.
, vol.34
, pp. 967-970
-
-
Klemens, S.P.1
Cynamon, M.H.2
Swenson, C.E.3
Ginsberg, R.S.4
-
60
-
-
0031943679
-
Rationale for and efficacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection
-
Leitzke S, Bucke W, Borner K, Muller R, Hahn H, Ehlers S. Rationale for and efficacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection, Antimicrob. Agents Chemother. 1998;42: 459-461.
-
(1998)
Antimicrob. Agents Chemother.
, vol.42
, pp. 459-461
-
-
Leitzke, S.1
Bucke, W.2
Borner, K.3
Muller, R.4
Hahn, H.5
Ehlers, S.6
-
61
-
-
0029129973
-
Formulation and efficacy of liposomeencapsulated antibiotics for therapy of intracellular Mycobacterium avium infection
-
Oh YK, Nix DE, Straubinger RM. Formulation and efficacy of liposomeencapsulated antibiotics for therapy of intracellular Mycobacterium avium infection, Antimicrob. Agents Chemother. 1995;39:2104-2111.
-
(1995)
Antimicrob Agents Chemother.
, vol.39
, pp. 2104-2111
-
-
Oh, Y.K.1
Nix, D.E.2
Straubinger, R.M.3
-
62
-
-
0029910034
-
Treatment of intracellular Mycobacterium avium complex infection by free and liposomeencapsulated sparfloxacin
-
Duzgunes N, Flasher D, Reddy MV, Luna-Herrera J, Gangadharam PR. Treatment of intracellular Mycobacterium avium complex infection by free and liposomeencapsulated sparfloxacin, Antimicrob. Agents Chemother. 1996;40:2618-2621.
-
(1996)
Antimicrob Agents Chemother.
, vol.40
, pp. 2618-2621
-
-
Duzgunes, N.1
Flasher, D.2
Reddy, M.V.3
Luna-Herrera, J.4
Gangadharam, P.R.5
-
63
-
-
0030890637
-
Lung specific liposomes: Stability, biodistribution and toxicity of liposomal antitubercular drugs in mice
-
Deol P, Khuller GK. Lung specific liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice, Biochem. Biophys. Acta 1997;1334:161-172.
-
(1997)
Biochem. Biophys. Acta
, vol.1334
, pp. 161-172
-
-
Deol, P.1
Khuller, G.K.2
-
64
-
-
0030918970
-
Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice
-
Deol P, Khuller GK, Joshi K. Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice, Antimicrob. Agents Chemother. 1997;41:1211-1214.
-
(1997)
Antimicrob Agents Chemother.
, vol.41
, pp. 1211-1214
-
-
Deol, P.1
Khuller, G.K.2
Joshi, K.3
-
65
-
-
0027368832
-
In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and Mycobacterium tuberculosis
-
Mehta RT, Keyhani A, McQueen TJ, Rosenbaum B, Rolston KV, Tarrand JJ. In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and Mycobacterium tuberculosis, Antimicrob. Agents Chemother. 1999;37:2584-2587.
-
(1999)
Antimicrob Agents Chemother.
, vol.37
, pp. 2584-2587
-
-
Mehta, R.T.1
Keyhani, A.2
McQueen, T.J.3
Rosenbaum, B.4
Rolston, K.V.5
Tarrand, J.J.6
-
66
-
-
0032798081
-
Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine
-
Adams LB, Sinha I, Franzblau SG, Krahenbuhl LJ, Mehta RT. Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine, Antimicrob. Agents Chemother. 1999;43:1638-1643.
-
(1999)
Antimicrob Agents Chemother.
, vol.43
, pp. 1638-1643
-
-
Adams, L.B.1
Sinha, I.2
Franzblau, S.G.3
Krahenbuhl, L.J.4
Mehta, R.T.5
-
67
-
-
33846193666
-
Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis
-
El-Ridy MS, Mostafa DM, Shehab A, E.A. Nasr, S.A. El-Alim, Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis, Int. J. Pharm. 2007;330:82-88.
-
(2007)
Int. J. Pharm.
, vol.330
, pp. 82-88
-
-
El-Ridy, M.S.1
Mostafa, D.M.2
Shehab, A.3
Nasr, E.A.4
El-Alim, S.A.5
-
68
-
-
37049038233
-
Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis
-
Gaspar MM, Cruz A, Penha AF, Reymao J, Sousa AC, Eleutério CV, Domingues SA, et al. Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis, Int. J. Antimicrob. Agents. 2008;32:37-45.
-
(2008)
Int. J. Antimicrob. Agents.
, vol.32
, pp. 37-45
-
-
Gaspar, M.M.1
Cruz, A.2
Penha, A.F.3
Reymao, J.4
Sousa, A.C.5
Eleutério, C.V.6
Domingues, S.A.7
-
69
-
-
39149118304
-
Advances in lipid nanodispersions for parenteral drug delivery and targeting
-
Constantinides PP, Chaubal MV, Shorr R. Advances in lipid nanodispersions for parenteral drug delivery and targeting, Adv. Drug Deliv. Rev. 2008;60:757-767.
-
(2008)
Adv. Drug Deliv. Rev.
, vol.60
, pp. 757-767
-
-
Constantinides, P.P.1
Chaubal, M.V.2
Shorr, R.3
-
70
-
-
84898695741
-
-
Morales D, Gutierrez JM, Garci{dotless}a-Celma MJ, Solans C, Langmuir. 2003;19:71-96.
-
(2003)
Langmuir
, vol.19
, pp. 71-96
-
-
Morales, D.1
Gutierrez, J.M.2
Garcia-Celma, M.J.3
Solans, C.4
-
71
-
-
56749107618
-
Potential of nanoemulsions for intravenous delivery of rifampicin
-
Ahmed M, Ramadan W, Rambhu D, Shakeel F. Potential of nanoemulsions for intravenous delivery of rifampicin, Pharmazie 2008;63:806-811.
-
(2008)
Pharmazie
, vol.63
, pp. 806-811
-
-
Ahmed, M.1
Ramadan, W.2
Rambhu, D.3
Shakeel, F.4
-
72
-
-
4544383493
-
Nanosuspensions in drug delivery
-
Rabinow BE. Nanosuspensions in drug delivery, Nat. Rev. Drug Discov. 2004;3:785-796.
-
(2004)
Nat Rev. Drug Discov.
, vol.3
, pp. 785-796
-
-
Rabinow, B.E.1
-
73
-
-
0033965872
-
Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection
-
Peters K, Leitzke S, Diederichs JE, Borner K, Hahn H, Müller RH, et al. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection, J. Antimicrob. Chemother. 2000;45:7783.
-
(2000)
J. Antimicrob. Chemother.
, vol.45
, pp. 7783
-
-
Peters, K.1
Leitzke, S.2
Diederichs, J.E.3
Borner, K.4
Hahn, H.5
Müller, R.H.6
-
74
-
-
0037190027
-
Rifampicin microparticles production by supercritical antisolvent precipitation
-
Reverchon E, De Marco I, Della Porta G. Rifampicin microparticles production by supercritical antisolvent precipitation, Int. J. Pharm.2002;243:83-91.
-
Int. J. Pharm
, vol.2002
, pp. 243
-
-
Reverchon, E.1
de Marco, I.2
Della Porta, G.3
-
75
-
-
0037678925
-
Micronization of antibiotics by supercritical assisted atomization
-
Reverchon E, Della Porta G. Micronization of antibiotics by supercritical assisted atomization, J. Supercrit. Fluids 2003;26:243-252.
-
(2003)
J. Supercrit. Fluids
, vol.26
, pp. 243-252
-
-
Reverchon, E.1
Della Porta, G.2
-
77
-
-
0029052419
-
Preparation and characterization of niosomes containing rifampicin for lung targeting
-
Jain CP, Vyas SP. Preparation and characterization of niosomes containing rifampicin for lung targeting, J. Microencapsul 1995;12:401-407.
-
(1995)
J. Microencapsul
, vol.12
, pp. 401-407
-
-
Jain, C.P.1
Vyas, S.P.2
-
78
-
-
33846162000
-
Niosomal system for delivery of rifampicin to lymphatics
-
Jain CP, Vyas SP, Dixit VK. Niosomal system for delivery of rifampicin to lymphatics, Indian J. Pharm. Sci.2006;68:575-578.
-
Indian J. Pharm. Sci
, vol.2006
, pp. 68
-
-
Jain, C.P.1
Vyas, S.P.2
Dixit, V.K.3
-
79
-
-
1942505838
-
Lung accumulation of niosome-entrapped rifampicin following intravenous and intratracheal administration in the rat
-
Mullaicharam AR, Murthy RSR. Lung accumulation of niosome-entrapped rifampicin following intravenous and intratracheal administration in the rat, J. Drug Deliv. Sci. Technol. 2004;14:99-104.
-
(2004)
J. Drug Deliv. Sci. Technol.
, vol.14
, pp. 99-104
-
-
Mullaicharam, A.R.1
Murthy, R.S.R.2
-
80
-
-
1642460578
-
Nanosuspension as the most promising approach in nanoperticulate drug delivery system
-
Rao GC, Kumar MS, Mathivanon N, Rao ME. Nanosuspension as the most promising approach in nanoperticulate drug delivery system, pharmazie. 2004;59:5.
-
(2004)
Pharmazie.
, vol.59
, pp. 5
-
-
Rao, G.C.1
Kumar, M.S.2
Mathivanon, N.3
Rao, M.E.4
-
83
-
-
17444377960
-
Antitubercular inhaled therapy: Opportunities, progress and challenges
-
Pandey R, Khuller GK. Antitubercular inhaled therapy: opportunities, progress and challenges. J Antimicrobial Chemotherapy 2005;55:430-435.
-
(2005)
J Antimicrobial Chemotherapy
, vol.55
, pp. 430-435
-
-
Pandey, R.1
Khuller, G.K.2
-
84
-
-
0347519282
-
Poly (DL-lactide-co glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis
-
Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK, Prasad B. Poly (DL-lactide-co glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 2003;52:981-986.
-
(2003)
J Antimicrob Chemother
, vol.52
, pp. 981-986
-
-
Pandey, R.1
Sharma, A.2
Zahoor, A.3
Sharma, S.4
Khuller, G.K.5
Prasad, B.6
-
85
-
-
6344277290
-
Lectin-functionalized poly (lactideco-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis
-
Sharma A, Sharma S, Khuller GK. Lectin-functionalized poly (lactideco-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother 2004;54:761-766.
-
(2004)
J Antimicrob Chemother
, vol.54
, pp. 761-766
-
-
Sharma, A.1
Sharma, S.2
Khuller, G.K.3
-
86
-
-
20444385102
-
Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis
-
Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb) 2005;85:227-234.
-
(2005)
Tuberculosis (Edinb)
, vol.85
, pp. 227-234
-
-
Pandey, R.1
Khuller, G.K.2
-
87
-
-
3042586026
-
Physical chemical considerations of lipid-based oral drug delivery: Solid lipid nanoparticles
-
Bummer PM. Physical chemical considerations of lipid-based oral drug delivery: solid lipid nanoparticles. Crit Rev Ther Drug Carrier Syst 2004;21:1-20.
-
(2004)
Crit Rev Ther Drug Carrier Syst
, vol.21
, pp. 1-20
-
-
Bummer, P.M.1
|